Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arbutus BiopharmaABUS +4.52%51 Equity-to-Asset is 0.94 as of Mar. 2026, which is 24% above its 10-year median of 0.76. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $50.35 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Arbutus Biopharma ranks better than 91.88% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Arbutus Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $260.2 Mil. Arbutus Biopharma's Total Assets for the quarter that ended in Mar. 2026 was $277.2 Mil.
Therefore, Arbutus Biopharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.94.
The historical rank and industry rank for Arbutus Biopharma's Equity-to-Asset or its related term are showing as below:
ABUS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67 Med: 0.76 Max: 0.94
Current: 0.94
During the past 13 years, the highest Equity to Asset Ratio of Arbutus Biopharma was 0.94. The lowest was 0.67. And the median was 0.76.
ABUS's Equity-to-Asset is ranked better than 91.88% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs ABUS: 0.94
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Arbutus Biopharma Equity-to-Asset Related Terms
Arbutus Biopharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABUS vs TBPH, ANNX, SANA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Arbutus Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Arbutus Biopharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a Equity-to-Asset of 0.94 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arbutus Biopharma and its competitors. This is 24% above median its historical median of 0.76. Over the past decade, Arbutus Biopharma's Equity-to-Asset has ranged from 0.67 to 0.94. According to the industry distribution chart, Arbutus Biopharma ranks #115 out of 1416 companies in the Biotechnology industry, placing it in the top 8.1%.
Is Arbutus Biopharma's Equity-to-Asset too high?
Arbutus Biopharma's current Equity-to-Asset of 0.94 is 24% above median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 0.94. The Biotechnology industry median Equity-to-Asset is 0.68. Arbutus Biopharma's value of 0.94 is 38.2% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #115 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Equity-to-Asset compare to TBPH and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #115 out of 1416 companies for Equity-to-Asset. This places Arbutus Biopharma in the top 8% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Arbutus Biopharma's value of 0.94 is 38.2% above this benchmark. Historically, Arbutus Biopharma's own Equity-to-Asset has ranged from 0.67 to 0.94 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.68, Arbutus Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Equity-to-Asset of 0.94 is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Equity-to-Asset is 0.94, which is 24% above median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $50.35, compared to a current price of $4.61 — trading 90.8% below its estimated fair value. The current Equity-to-Asset is 0.94, which is 24% above median its 10-year median of 0.76 and 38.2% above the Biotechnology industry median of 0.68. Arbutus Biopharma's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Equity-to-Asset is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.61 is trading 90.8% below its estimated GF Value™ of $50.35.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Equity-to-Asset: 0.94 (24% above median its 10-year median of 0.76)
GF Value™: $50.35 vs. price of $4.61 (90.8% below fair value)
Industry Position: 38.2% above the Biotechnology median (#115 of 1416)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score
Get the complete analysis for ABUS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
